What's Happening?
A recent study published in the journal Hepatology reveals that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent liver cancer. Conducted
by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat and fibrosis but also suppresses liver cancer linked to fatty liver disease. The research identified the Midkine (MDK) gene and its receptor as a significant cancer-promoting pathway, which Resmetirom appears to modulate. The study highlights the potential of Resmetirom to improve liver metabolism, reduce liver fat, and reshape the immune microenvironment, suggesting a new prevention-oriented treatment model for high-risk patients.
Why It's Important?
The findings of this study are significant as they offer a potential new strategy for preventing liver cancer in patients with fatty liver disease, a condition that is becoming increasingly common due to rising obesity and metabolic disorders. Hepatocellular carcinoma (HCC), a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Current treatments for advanced liver cancer, such as immune checkpoint inhibitors, are less effective in patients with fatty liver-related liver cancer. The study's insights into the MDK pathway and the potential of Resmetirom to target this pathway could lead to improved outcomes for these patients, offering a new avenue for treatment and prevention.
What's Next?
The research team plans to validate relevant biomarkers in larger patient cohorts and collaborate with clinicians to design clinical trials that combine Resmetirom with immunotherapy and targeted therapy. This approach aims to establish a prevention-oriented treatment model for patients at high risk of developing liver cancer due to fatty liver disease. If successful, this could lead to new clinical guidelines and treatment protocols, potentially reducing the incidence of liver cancer in this growing patient population.
